In vivo efficacy of apramycin in murine infection models

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6938-6941

  Meyer, Martin ^a   Freihofer, Pietro ^a   Scherman, Michael ^b   Teague, Joanne ^c   Lenaerts, Anne ^b   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c Euprotec Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; APRAMYCIN; CEFOXITIN; CIPROFLOXACIN; KANAMYCIN; LINEZOLID; OXACILLIN; PAROMOMYCIN; RNA 16S; ANTIINFECTIVE AGENT; GAMMA INTERFERON; NEBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STAPHYLOCOCCAL BACTEREMIA; TUBERCULOSIS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; TUBERCULOSIS, PULMONARY;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; INTERFERON-GAMMA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, KNOCKOUT; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NEBRAMYCIN; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; TUBERCULOSIS, PULMONARY;

EID: 84908565694     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03239-14     Document Type: Article

References (27)

1. French GL. 2010. The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents 36(Suppl 3):S3-S7. http://dx.doi.org/10.1016/S0924-8579(10)70003-0
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011
4. Davies J. 2007. In the beginning there was streptomycin, p 1-13. In Arya DP (ed), Aminoglycoside antibiotics: from chemical biology to drug discovery. John Wiley & Sons, Inc., Hoboken, NJ
5. Chambers HF. 1996. Chemotherapy of microbial diseases, p 1103-1121. In Hardman JG, Limbird LE (ed), Goodman & Gilman's The pharmaceutical basis of therapeutics, 10th ed. McGraw-Hill, New York, NY
6. Houghton JL, Green KD, Chen W, Garneau-Tsodikova S. 2010. The future of aminoglycosides: the end or renaissance? Chembiochem 11: 880-902. http://dx.doi.org/10.1002/cbic.200900779
7. Wright GD, Berghuis AM, Mobashery S. 1998. Aminoglycoside antibiotics: structure, function and resistance, p 27-69. In Rosen BP, Mobashery S (ed), Resolving the antibiotic paradox. Springer, New York, NY
8. Galimand M, Courvalin P, Lambert T. 2003. Plasmid-mediated highlevel resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob. Agents Chemother. 47:2565-2571. http://dx.doi.org/10.1128/AAC.47.8.2565-2571.2003
9. Doi Y, Arakawa Y. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88-94. http://dx.doi.org/10.1086/518605
10. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54:4636-4642. http://dx.doi.org/10.1128/AAC.00572-10
11. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66:48-53. http://dx.doi.org/10.1093/jac/dkq408
12. O'Connor S, Lam LK, Jones ND, Chaney MO. 1976. Apramycin, a unique aminocyclitol antibiotic. J. Org. Chem. 41:2087-2092. http://dx.doi.org/10.1021/jo00874a003
13. Ryden R, Moore BJ. 1977. The in vitro activity of apramycin, a new aminocyclitol antibiotic. J. Antimicrob. Chemother. 3:609-613. http://dx.doi.org/10.1093/jac/3.6.609
14. Matt T, Ng CL, Lang K, Sha SH, Akbergenov R, Shcherbakov D, Meyer M, Duscha S, Xie J, Dubbaka SR, Perez-Fernandez D, Vasella A, Ramakrishnan V, Schacht J, Bottger EC. 2012. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc. Natl. Acad. Sci. U. S. A. 109:10984-10989. http://dx.doi.org/10.1073/pnas.1204073109
15. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416. http://dx.doi.org/10.1164/rccm.200604-571ST
16. Sturdy A, Goodman A, Jose RJ, Loyse A, O'Donoghue M, Kon OM, Dedicoat MJ, Harrison TS, John L, Lipman M, Cooke GS. 2011. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J. Antimicrob. Chemother. 66: 1815-1820. http://dx.doi.org/10.1093/jac/dkr221
17. Forge A, Schacht J. 2000. Aminoglycoside antibiotics. Audiol. Neurootol. 5:3-22. http://dx.doi.org/10.1159/000013861
18. Duggal P, Sarkar M. 2007. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term followup. BMC Ear Nose Throat Disord. 7:5. http://dx.doi.org/10.1186/1472-6815-7-5
19. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47:783-785. http://dx.doi.org/10.1128/AAC.47.2.783-785.2003
20. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 92: 453-488. http://dx.doi.org/10.1016/j.tube.2012.07.003
21. Perez-Fernandez D, Shcherbakov D, Matt T, Leong NC, Kudyba I, Duscha S, Boukari H, Patak R, Dubbaka SR, Lang K, Meyer M, Akbergenov R, Freihofer P, Vaddi S, Thommes P, Ramakrishnan V, Vasella A, Bottger EC. 2014. 4=-O-substitutions determine selectivity of aminoglycoside antibiotics. Nat. Commun. 5:3112. http://dx.doi.org/10 .1038/ncomms4112
22. Sander P, Prammananan T, Böttger EC. 1996. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol. Microbiol. 22:841-848. http://dx.doi.org/10.1046/j.1365-2958.1996.01532.x
23. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. 2010. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 77:830-840. http://dx.doi.org/10.1111/j.1365-2958.2010.07218.x
24. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace, RJ, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581. http://dx.doi.org/10.1086/515328
25. Prammananan T, Sander P, Springer B, Böttger EC. 1999. RecAmediated gene conversion and aminoglycoside resistance in strains heterozygous for rRNA. Antimicrob. Agents Chemother. 43:447-453. http://dx.doi.org/10.1093/jac/43.4.447
26. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602. http://dx.doi.org/10.1016/S1473-3099(10)70143-2
27. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435. http://dx.doi.org/10.1001/archinte.165.12 .1430.